Table 8.
Overview of the clinical trials involving the use of MSCs in MS patients.
| MSCs | MSCs Administration | Severe Adverse Events | Improvements | Ref. |
|---|---|---|---|---|
| Autologous BM-MSCs | A mean of 57 × 106 cells; intrathecally | No | Yes | [105] |
| UCMSC | 1 to 2 × 106 cells/kg; i.v. at 3-month intervals for 7 times |
No | Yes | [106] |
| Autologous SVF | Patients received intraventricular SVF injection volumes of 3.5–20 cc (median: 4 cc) containing 4.05 × 105 to 6.2 × 107 cells/cc and contained on average 8% hematopoietic and 7.5% ADSCs |
- | Yes | [107] |
| SVF | 4.2 × 106 cells (females) and 12.8 × 106 cells (males); intrathecally | No | - | [108] |
BM-MSCs, bone marrow MSCs; SVF, Stromal vascular fraction; UCMSCs, Umbilical cord MSCs.